Any new drug launch must overcome numerous obstacles in the pursuit of success
“Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc.” So how does this differ for a small and emerging biotech firm?”
In an article published earlier this year, Envision Pharma Group’s Rachel Shemer, along with Two Labs Angus Bromley and Kimberly Cash, discuss the advantages and challenges smaller companies face.